EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29 September 2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca (LSE: AZN) and is in no danger of being side-lined, according to the firm’s UK marketing director Chris Boulton. Speaking to The Pharma Letter at the impressive AstraZeneca stand at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting in Vienna last week, Mr Boulton said that AstraZeneca is fighting to be at the forefront of the global race to treat diabetes.

Surrounded by stands representing huge brands such as Sanofi, Boehringer and Novo Nordisk, he said AstraZeneca is one of the leading pharma majors competing to manage the disease better, in part due to the company’s strong portfolio of diabetes products.

Global epidemic

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK